Combined-modality therapy for unresectable, stage III non-small-cell lung cancer--caveat emptor or caveat venditor?
- PMID: 8780621
- DOI: 10.1093/jnci/88.17.1175
Combined-modality therapy for unresectable, stage III non-small-cell lung cancer--caveat emptor or caveat venditor?
Comment in
-
Re: Combined-modality therapy for unresectable, stage III non-small-cell lung cancer--caveat emptor or caveat venditor?J Natl Cancer Inst. 1996 Dec 18;88(24):1866-7. doi: 10.1093/jnci/88.24.1866. J Natl Cancer Inst. 1996. PMID: 8961980 No abstract available.
Comment on
-
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5. doi: 10.1093/jnci/88.17.1210. J Natl Cancer Inst. 1996. PMID: 8780630 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
